SCHEMBL835232

SCHEMBL835232

Cc1ccc(Sc2cc(=O)n(C)c3cc(C)c(C)cc23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
NQO2 P16083 1/20 0.44
PRNP P04156 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
RHEB Q15382 1/20 0.41
NTSR1 P30989 1/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
POLB P06746 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HTT P42858 1/20 0.41
LMNA P02545 2/20 0.37
HKDC1 Q2TB90 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 4/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL835229 0.89 NQO2 (0.42) KDM4ENQO2PRNPRXFP1RHEB
SCHEMBL835023 0.89 KDM4E (0.42) KDM4ENQO2PRNPRXFP1MEN1
SCHEMBL836066 0.87 RXFP1 (0.48) KDM4ENQO2PRNPRXFP1MEN1
SCHEMBL14300144 0.84 RXFP1 (0.58) KDM4ENQO2PRNPRXFP1MEN1
SCHEMBL836061 0.82 ALDH1A1 (0.54) KDM4EPRNPRXFP1MEN1KMT2A
SCHEMBL835001 0.82 RXFP1 (0.44) KDM4ENQO2PRNPRXFP1MEN1
SCHEMBL836065 0.80 MAPT (0.47) KDM4EPRNPRXFP1MEN1KMT2A
SCHEMBL836059 0.79 RHEB (0.50) KDM4ENQO2PRNPRXFP1MEN1
SCHEMBL14302623 0.79 LMNA (0.43) KDM4ENQO2PRNPRXFP1MEN1
SCHEMBL829660 0.79 MEN1 (0.43) KDM4ENQO2PRNPRXFP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A KDM4E 1265/4885NQO2 20/4885PRNP 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.